Cargando…
B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow
Persistence of residual disease after induction chemotherapy is a strong predictor of relapse in acute lymphoblastic leukemia (ALL). The bone marrow microenvironment may support escape from treatment. Using three-dimensional fluorescence imaging of ten primary ALL xenografts we identified sites of p...
Autores principales: | Barz, Malwine J., Behrmann, Lena, Capron, Danaëlle, Zuchtriegel, Gabriele, Steffen, Fabio D., Kunz, Leo, Zhang, Yang, Vermeerbergen, Iria Jimenez, Marovca, Blerim, Kirschmann, Moritz, Zech, Antonia, Nombela-Arrieta, César, Ziegler, Urs, Schroeder, Timm, Bornhauser, Beat, Bourquin, Jean-Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153534/ https://www.ncbi.nlm.nih.gov/pubmed/36325888 http://dx.doi.org/10.3324/haematol.2021.280451 |
Ejemplares similares
-
CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022) -
CLL-050 Induction of Neutralizing Antibodies in Chronic Lymphocytic Leukemia Patients After SARS-CoV-2 mRNA Vaccination: A Monocentric Experience
por: Mavilia, Fabrizio, et al.
Publicado: (2022) -
CLL-224 Coronavirus Disease Mortality and Outcome in Macedonian Patients With Chronic Lymphocytic Leukemia: Single-Center Experience
por: Trajkova, Sanja, et al.
Publicado: (2022) -
ALL-083 ALLogeneic Hematopoietic Stem Cell Transplantation of a R/R T-ALL Patient Given Nelarabine, 3 Weeks Post Moderate COVID-19 Infection in the Local Setting
por: Uong, Flaryll
Publicado: (2022) -
CLL-211 Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia (CLL) and Indolent Non-Hodgkin Lymphoma (NHL): Results From a Large, Single-Center Observational Study
por: St-Pierre, Frédérique, et al.
Publicado: (2022)